NASDAQ · Drug Manufacturers - Specialty & Generic

BioDelivery Sciences International, Inc. (BDSI) Stock

$5.59 -0.09% NASDAQ: BDSI Healthcare

BioDelivery Sciences International, Inc. (BDSI) is a specialized pharmaceutical firm dedicated to the advancement and commercialization of therapeutic products designed for long-term health conditions, serving markets both within the United States and internationally.

Valuation

MetricValue
Price$5.59
Market Cap$577.05M
P/E Ratio6.82
P/B Ratio3.07
P/S Ratio3.46
EPS (TTM)$0.82
52-Week High$5.62
52-Week Low$2.50
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE57.33%
ROA26.14%
ROCE15.33%
Gross Margin85.98%
Operating Margin22.27%
Net Margin50.90%
Debt/Equity0.31
Current Ratio2.45

Annual Financials (USD)

Metric20172018201920202021
Revenue$62.0M$56.0M$111.0M$156.0M$167.0M
Operating Profit$-29.0M$-24.0M$4.0M$33.0M$37.0M
Net Profit$5.0M$-34.0M$-15.0M$26.0M$85.0M
EPS$0.09$-0.54$-0.18$0.24$0.82
Op Margin-47.5%-42.5%3.4%21.1%22.3%

Balance Sheet (USD)

Metric20172018201920202021
Total Assets$88.0M$109.0M$183.0M$240.0M$325.0M
Total Liabilities$79.0M$79.0M$113.0M$132.0M$137.0M
Cash$21.0M$44.0M$64.0M$112.0M$114.0M
Borrowings$48.0M$52.0M$59.0M$78.0M$59.0M

Cash Flow (USD)

Metric20172018201920202021
Operating Cash Flow$-32.0M$-24.0M$11.0M$25.0M$41.0M
Investing Cash Flow$-12.0M$-4.0M$-31.0M$0$-7.0M
Financing Cash Flow$-3.0M$-1.0M$2.0M$3.0M$-11.0M
Net Cash Flow$-11.0M$23.0M$20.0M$48.0M$3.0M
Free Cash Flow$-38.0M$-26.0M$11.0M$25.0M$41.0M

Valuation & Return Ratios

MetricValue
PEG Ratio0.03
EV / EBITDA11.71
FCF Yield7.04%
Quick Ratio2.17
Interest Coverage4.95
Return 1Y—
Return 3Y—
Return 5Y—

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
ACCDAccolade, Inc. $7.02 +0.00% -5.28 $575.59M 0.00%
ALIMAlimera Sciences, Inc. $5.54 -0.18% -7.01 $301.29M 0.00%
APENApollo Endosurgery, Inc. $10.00 +0.00% -10.20 $579.72M 0.00%
EXAIExscientia plc $4.84 — -3.06 $633.18M 0.00%
GRALVGRAIL, Inc. Common Stock $18.63 +8.19% — $579.39M 0.00%

About BioDelivery Sciences International, Inc.

BioDelivery Sciences International, Inc. (BDSI) is a specialized pharmaceutical firm dedicated to the advancement and commercialization of therapeutic products designed for long-term health conditions, serving markets both within the United States and internationally. The company's product offerings leverage its proprietary BioErodible MucoAdhesive drug delivery system—a slender, dissolving polymer film intended for application to the inner cheek—in addition to other drug administration methodologies. Its portfolio includes several key products: BELBUCA, a buprenorphine buccal film, is utilized for the ongoing management of persistent pain. Symproic functions as a peripherally acting mu-opioid receptor antagonist, specifically addressing opioid-induced constipation in adult patients suffering from chronic non-cancer pain. This also covers individuals whose chronic pain is a result of prior cancer or its treatment, provided they do not require frequent increases in opioid dosage. ELYXYB, an oral solution containing celecoxib, provides treatment for adult migraines, irrespective of the presence of an aura. ONSOLIS, a soluble fentanyl film administered buccally, is intended for the management of sudden, severe "breakthrough" pain experienced by cancer patients. Founded in 1997, BioDelivery Sciences International, Inc. is headquartered in Raleigh, North Carolina. As of March 18, 2022, the company operates as a subsidiary of Collegium Pharmaceutical, Inc.

BioDelivery Sciences International, Inc. is headquartered in US.

BioDelivery Sciences International, Inc. (BDSI) stock trades at $5.59 with a market capitalization of $577.05M. The stock is valued at a price-to-earnings (P/E) ratio of 6.82, price-to-book of 3.07, price-to-sales of 3.46. Over the past 52 weeks the stock has ranged between $2.50 and $5.62, and currently trades at its 52-week high.

On profitability, BioDelivery Sciences International, Inc. generates a return on equity (ROE) of 57.33% — well above the market average, a sign of a high-quality business, return on capital employed of 15.33%, an operating margin of 22.27%, a net profit margin of 50.90%.

Official website: www.bdsi.com

Related Healthcare Stocks

LLY Drug Manufacturers - General $1185.71 -0.52% JNJ Drug Manufacturers - General $259.24 +0.88% ABBV Drug Manufacturers - General $246.04 +0.89% UNH Medical - Healthcare Plans $407.08 +0.77% MRK Drug Manufacturers - General $128.57 +0.16% NVS Drug Manufacturers - General $158.83 -0.64% NVO Biotechnology $51.58 +1.22% TMO Medical - Diagnostics & Research $594.00 +2.41% AMGN Drug Manufacturers - General $387.64 -1.39% ABT Medical - Devices $108.03 +0.70% GILD Drug Manufacturers - General $132.73 -1.18% PFE Drug Manufacturers - General $26.74 +2.06%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksNasdaq High ROE StocksAll stock screens
Run Stock Screener Investing Guides